Scientists at VCU Massey Cancer Center may have uncovered a primary method through which cancer cells exist undetected in an organism and received more than $1 million to investigate the potential for novel therapeutics that target and destroy cells in a specific state of tumor dormancy.
If a genetically or synthetically engineered organism gets into the environment, how will we tell it apart from the millions of naturally occurring microorganisms? Recently, the US government and research scientists have identified a need for new tools that can detect engineered organisms that have been accidentally or intentionally released beyond the lab. With scientists from Raytheon and other universities, WPI chemical engineer Eric Young is helping develop a detection tool based on DNA signatures.
An analysis of 117 cancer drugs approved by the US FDA over a 20-year period finds the drugs took a median of 6.5 years to go from the first clinical trial in adults to the first trial in children. 'As a doctor taking care of young cancer patients, this is tremendously frustrating,' says lead researcher Steven DuBois, M.D. 'If I were a parent of a child with cancer, I wouldn't stand for this.'
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.
The anti-tumor protein p53 can decide on the life or death of a cell: If it detects damage in the cell's genome, the protein pushes the cell to suicide. New research conducted at Technical University of Munich (TUM) shows that this inborn cancer prevention only works when special proteins, known as chaperones, allow it to take place.
'This study shows that [rare pulmonary side effects of brigatinib] can disappear within days despite continued exposure to the drug,' says D. Ross Camidge, M.D., Ph.D.
Researchers (UNIGE) have devised a cell co-culture platform that reproduces a patient's tumor structure in 3D. The scientists can use it to test several drugs or their combinations at different stages of the tumor's development. They now need only five days to identify which treatment will be most effective for a particular case, and the combination can then be translated for clinical practice.
New research supports the effectiveness and safety of esketamine nasal spray in treating depression in people who have not responded to previous treatment. The research will be published online today in the American Journal of Psychiatry. This study is one of the key studies that led to the recent Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression.
A new study advocates for exercise as the primary method of treatment and intervention, rather than psychotropic medications, within inpatient psychiatric facilities.
Medical University of South Carolina investigators have exploited a metabolic quirk of certain cancers known as glutamine addiction to identify a potential new therapy for esophageal cancer. After characterizing the pathway involved in cancer progression, they tested a new combination treatment in both cells and animal models, with promising results. The next step is to secure funding to bring the new combination regimen to clinical trial. Their findings are reported in Nature Communications.